Assembly Biosciences Initiates Phase 2a Trial for HBV Core Inhibitor (Healio)
UF Innovate | Sid Martin Biotech alumni company Assembly Bioscience announced the initiation of two randomized control phase 2a trials for ABI-H0731, the company’s lead hepatitis B core inhibitor, according to a press release. ABI-H0731 previously demonstrated potent antiviral activity in a phase 1b trial, the results of which were presented at the International Liver […]